IBA Announces 2016 Guidance and Upgrades 2015 Expectations

Louvain-La-Neuve, Belgium, 17 February 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today provides an update on 2016 guidance and 2015 unaudited preliminary expectations ahead of full year 2015 financial results on 24 March 2016.

FY15 Financial Highlights

- Revenues for the full year ending 31 December 2015 expected to be around EUR 270 million up more than 20% from EUR 220.6 million at 31 December 2014

- REBIT for the full year ending 31 December 2015 expected to be up more than 20% from EUR 22.9 million at 31 December 2014, slightly above 10% REBIT margin guidance

- Record order intake in 2015 and robust backlog now standing at around EUR 330 million in Proton Therapy and Other Accelerators at the end of December 2015, up 30% from EUR 256.2 million at 31 December 2014

- 33 ongoing Proton Therapy service and maintenance contracts signed in total, representing a backlog of about EUR 575 million of revenue over the next 10-15 years up from 27 contracts representing EUR 468 million at 31 December 2014

- Dosimetry backlog above EUR 18.0 million, up more than 9% from EUR 16.8 million at 31 December 2014

- Net profit positively impacted by more than EUR 30 million non recurring profit including the capital gain on disposal of IBA Molecular

- Net cash position of approximately EUR 50 million as of 31 December 2015, versus EUR 5.3 million at 31 December 2014